Trial ID or NCT#

NCT02562755

Status

NOT RECRUITING

Purpose

This is a randomized Phase 3 study to determine whether treatment with vaccinia virus based immunotherapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib in patients with advanced hepatocellular carcinoma who have not received prior systemic therapy.

Official Title

A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Nishita Kothary, MD
Interventional radiologist
Professor of Radiology (Interventional Radiology) at the Stanford University Medical Center
Daniel Sze, MD, PhD
Interventional radiologist
Professor of Radiology (Interventional Radiology) at the Stanford University Medical Center
David S. Wang, MD
Interventional radiologist, Radiologist
Clinical Assistant Professor, Radiology
Bernice Kwong, MD
Dermatologist, Dermatologic oncologist, Cutaneous oncology specialist, Dermato-oncology specialist, Dermatopathologist
Clinical Associate Professor, Dermatology

Contact us to find out if this trial is right for you.

CONTACT

Shawn Niknam
(650) 721-4080